Progressive Choreiform Movements in a Child: Early Recognition and Management of Sydenham Chorea
Jason M. Jaronik, Nicholas A. Scott, Bruce D. Harley, Phillip L. Marsh, Hassaan A. Khan, Sufyan Zackariya, Anna M. Tincher, Anthony V. Thomas, Mahmoud D. Al-Fadhl, John R. Bales, Morgan C. Lain, Uzma Rizvi, Randall J. Bjork, Mark M. Walsh

TL;DR
This paper presents a case of Sydenham chorea in a child, emphasizing early recognition and multidisciplinary care for better outcomes.
Contribution
The paper provides a detailed case study highlighting early symptoms and management strategies for Sydenham chorea.
Findings
Sydenham chorea can progress from subtle symptoms to severe movements in children.
Early recognition and multidisciplinary care improve outcomes in this rare condition.
Medication vigilance is crucial in managing Sydenham chorea effectively.
Abstract
Sydenham chorea, a rare neurological manifestation of acute rheumatic fever, persists in developed countries due to rheumatogenic strains of group A streptococcus. This case demonstrates the evolution from subtle early symptoms to definitive severe choreiform movements in Sydenham chorea in a 10-year-old female. This case highlights the importance of early recognition, multidisciplinary management, and vigilance in medication administration to optimize outcomes in rare conditions such as Sydenham chorea. This case highlights the diagnostic and management challenges of Sydenham chorea, showcasing its progression from subtle early symptoms to definitive severe choreiform movements. It demonstrates the importance of early recognition, multidisciplinary care, and cautious medication administration to optimize outcomes in this rare neurological condition associated with rheumatic fever.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsObsessive-Compulsive Spectrum Disorders · Hereditary Neurological Disorders · Botulinum Toxin and Related Neurological Disorders
Background
Sydenham chorea, though rare in developed countries due to widespread antibiotic access, remains a significant neurological manifestation associated with acute rheumatic fever [12]. This case highlights the challenges in diagnosing and managing this condition, emphasizing the importance of early identification and appropriate therapeutic strategies.
Case Report
A 10-year-old girl presented to the ED with nonspecific, rapid involuntary movements of the extremities initially described as twitching. Two weeks earlier, she had streptococcal pharyngitis treated with amoxicillin. This history combined with her symptoms raised suspicion for Sydenham chorea. An antistreptolysin O titer (ASO) was ordered, and she was discharged with instructions to return if symptoms worsened. Over six days, her symptoms progressed to severe motor impairment, prompting her return. The ASO was elevated at 888 Todd units (normal: 200–310). Examination revealed sporadic choreiform movements of the head, neck, torso, and extremities with the left arm more affected compared to the right (see Video 1). She also demonstrated sporadic transitioning between normal speech and laughter.
The video shows a 10-year-old female exhibiting sporadic choreiform movements of the arms, legs, torso, neck, and head consistent with Sydenham chorea.
Labs showed low creatinine (0.53 mg/dL), low ammonia (58 mcg/dL), and low valproic acid (40 mcg/mL). Her head CT and MRI were unremarkable. Echocardiography revealed aortic and mitral regurgitation. The combination of her clinical presentation and diagnostic workup met the Jones criteria for acute rheumatic fever. Treatment included 4.8 million units penicillin G benzathine, 60 mg prednisone daily, 500 mg valproic acid twice daily, and 1 mg haloperidol twice daily. Haloperidol was added to the treatment regimen primarily for its proven efficacy in reducing the involuntary movements associated with Sydenham chorea. After 18 days of admission, rehabilitation, and therapy, her symptoms had significantly improved, and she was discharged on a prednisone taper and 1 mg haloperidol twice daily. On follow-up evaluation, she reported complete resolution of symptoms and was able to attend school with no issues.
Discussion
Although rare in developed nations, Sydenham chorea persists due to rheumatogenic group A streptococcal strains, requiring clinical suspicion after streptococcal infections [1]. Sydenham chorea can be difficult to identify because of its rarity and the non-specific nature of its early presentation. Also, it can develop up to several months after streptococcal pharyngitis [12]. Thorough history-taking of recent streptococcal pharyngitis and the presence of other features of rheumatic fever, such as carditis, arthritis, and erythema marginatum-type rash [3] will allow the clinician to pursue laboratory confirmation with an ASO.
This case demonstrated rapid progression from the non-specific initial presentation—which was likely mild, large-amplitude early choreiform movements—to the more severe definitive chorea. Elevated ASO confirmed the diagnosis, enabling early intervention. Collaboration with pediatric neurology allowed comprehensive management. The patient’s improvement highlighted the efficacy of our therapeutic approach.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Bonthius DJ, Karacay B. Sydenham’s chorea: not gone and not forgotten. Semin Pediatr Neurol. 2003 Mar; 10(1): 11–9. DOI: 10.1016/S 1071-9091(02)00004-912785743 · doi ↗ · pubmed ↗
- 2Oosterveer DM, Overweg-Plandsoen WC, Roos RA. Sydenham’s chorea: a practical overview of the current literature. Pediatr Neurol. 2010 Jul; 43(1): 1–6. DOI: 10.1016/j.pediatrneurol.2009.11.01520682195 · doi ↗ · pubmed ↗
- 3Gewitz MH, Baltimore RS, Tani LY, Sable CA, Shulman ST, Carapetis J, Remenyi B, Taubert KA, Bolger AF, Beerman L, Mayosi BM, Beaton A, Pandian NG, Kaplan EL. American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015 May · doi ↗ · pubmed ↗
